Abstract | BACKGROUND: METHODS: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies. RESULTS: CONCLUSIONS: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.
|
Authors | Edoardo Ferlazzo, Dorothee Kasteleijn-Nolst Trenite, Gerrit-Jan de Haan, Felix Felix Nitschke, Saija Ahonen, Sara Gasparini, Berge A Minassian |
Journal | Current pharmaceutical design
(Curr Pharm Des)
Vol. 23
Issue 37
Pg. 5662-5666
( 2017)
ISSN: 1873-4286 [Electronic] United Arab Emirates |
PMID | 28799509
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
|
Topics |
- Animals
- Anticonvulsants
(therapeutic use)
- Humans
- Myoclonic Epilepsies, Progressive
(drug therapy, pathology)
|